Lexiscan(r) (regadenoson) Injection, Solution
Product Images NDC 51662-1448

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lexiscan(r) (regadenoson) (NDC 51662-1448). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Adverse 1 (Adverse 1)

This is a table showing the incidence of certain side effects in a comparison between two medications, Lexiscan and Adenoscan. The side effects include dyspnea, headache, flushing, chest discomfort, angina pectoris or ST segment depression, dizziness, chest pain, nausea, abdominal discomfort, dysgeusia, and feeling hot. The percentages indicate the proportion of patients who experienced each side effect, with Lexiscan and Adenoscan having differing incidence rates for each side effect.*

FDA Label Image

Adverse 2 (Adverse 2)

The text shows data on the percentage of different types of rhythm or conduction abnormalities, such as first and second degree AV block and ventricular conduction abnormalities, during evaluations using LEXISCAN ADENOSCAN. The percentages are provided for two groups, one of 1275 individuals and the other of 645 individuals. The text appears to be a table or chart.*

FDA Label Image

Adverse 3 (Adverse 3)

This document provides information regarding two separate medical cohorts, one for Asthma and another for Chronic Obstructive Pulmonary Disease (COPD). Additionally, it presents data on the patients' respiratory adverse reactions and specific symptoms, such as dyspnea, wheezing, and FEV reduction. The data was obtained from a clinical trial involving Lexiscan and Placebo, with varying sample sizes.*

FDA Label Image

Adverse 4 (Adverse 4)

This text describes the results of a cardiac event study on two different groups. Group 1 underwent a LEXISCAN test 3 minutes after exercise, while Group 2 underwent the same test 1 hour after exercise. Abnormalities were observed in both groups, including STT depression and elevation, as well as acute coronary syndrome and myocardial infarction. However, Group 1 had a higher incidence of abnormalities than Group 2. The study involved 575 participants in Group 1 and 567 participants in Group 2.*

FDA Label Image

Syringe Carton Labeling (Carton Labeling)

FDA Label Image

Clinical P 1 (Clinical P 1)

This is a table displaying the percentage of population affected by changes in heart rate, systolic blood pressure, and diastolic blood pressure. The table indicates the percentage of people affected by changes in the measurements, such as an increase or decrease in bpm (beats-per-minute) or mm Hg (millimeters of mercury).*

FDA Label Image

Clinical P 2 (Clinical P 2)

This is a table with vital sign parameters for Group 1 and Group 2 of an MPI 1 LEXISCAN test, conducted either 3 minutes or 1 hour following exercise. The table shows the percentage of individuals with heart rate >100 bpm, increase >40 bpm, systolic blood pressure <90 mm Hg, decrease >35 mm Hg or >200 mm Hg, increase >50 mm Hg, or >180 mm Hg and increase of 5% or >20 mm Hg from baseline; and diastolic blood pressure <50 mm Hg, decrease >25 mm Hg or >115 mm Hg, or increase >30 mm Hg.*

FDA Label Image

Clinical S (Clinical S)

This is a report comparing the agreement rates between two studies named Adenoscan and Lexiscan. The text provides data on the agreement rates and rate difference between the two studies. It also includes 95% confidence intervals for both studies.*

FDA Label Image

Serialized Carton Labeling (Serialized Carton)

This is a description of a medication called Ansyr-Syringes. It contains 0.08 mg of regadenoson per mL and various other ingredients such as dibasic sodium phosphate, propylene glycol, and edetate disodium. It is stored at room temperature and is distributed by a company called HF Acquisition Co., LLC. The text also includes various other alphanumeric symbols and codes that are not available for interpretation.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.